glp-1 and anesthesia RA guidance roundup GLP-1 drugs and aspiration risk
Description
Food and Drug Administration approved an oral formulation of Semaglutide for weight management, allowing it to enter the obesity treatment market
Limiting therapy duration: 63% are placing caps on how long a member can use the medication
Similar to Ozempic face and butt, Ozempic feet are largely anecdotal
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
